<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00656305</url>
  </required_header>
  <id_info>
    <org_study_id>BM004</org_study_id>
    <nct_id>NCT00656305</nct_id>
  </id_info>
  <brief_title>ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain</brief_title>
  <official_title>A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic and Multiple Myeloma Bone Tumors for the Palliation of Pain in Patients Who Are Not Candidates for Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <brief_summary>
    <textblock>
      A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic
      Bone and Multiple Myeloma Tumors for the Palliation of Pain in Patients Who are not
      Candidates for Radiation Therapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Responders</measure>
    <time_frame>3 months post treatment</time_frame>
    <description>Using the Numerical Rating Score (NRS) for pain (0 being no pain and 10 being worst imaginable pain), each subject was rated as a Responder or Non-responder. A responder is defined as a subject with a reduction in NRS worst score from baseline of two (2) or more points, and no increase in pain medication use.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Change in Medication Use</measure>
    <time_frame>3 months post treatment</time_frame>
    <description>Medication Use change reported from baseline until of study. Medication use is quantified by &quot;morphine equivalent usage&quot; (measured separately from Responder/Non-responder definition for the primary endpoint)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) as Measured by Change in Bodily Pain Inventory (BPI) From Baseline</measure>
    <time_frame>3 months post treatment</time_frame>
    <description>The BPI-QOL questionnaire is designed to show the severity and interference of pain in the lives of patients. This is a 7-item questionnaire that asks respondents the extent to which pain interferes with their general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life using a 0-10 numerical rating scale in which 0 represents 'does not interfere' and 10 indicates 'completely interferes'. Responses to the 7 items are averaged to form the pain interference scale score. Lower scores are better, showing less interference in daily activities while higher scores show more interference and hence worse outcomes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Bone Metastases</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>ExAblate Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ExAblate Sham Arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ExAblate MRfFUS</intervention_name>
    <description>MR guided focused ultrasound.</description>
    <arm_group_label>ExAblate Sham Arm</arm_group_label>
    <arm_group_label>ExAblate Treatment Arm</arm_group_label>
    <other_name>MRgFUS</other_name>
    <other_name>FUS</other_name>
    <other_name>Focused Ultrasound</other_name>
    <other_name>MR guided Focused Ultrasound</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>sham comparator</description>
    <arm_group_label>ExAblate Sham Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Men and women age 18 and older

          2. Patients who are able and willing to give consent and able to attend all study visits

          3. Patients who are suffering from symptoms of bone metastases or multiple myeloma bone
             lesions and are radiation failure patients:

             Radiation failure candidates are those who have received radiation without adequate
             relief from metastatic bone pain as determined by the patient and treating physician,
             those for whom their treating physician would not prescribe radiation or additional
             radiation treatments, and those patients who refuse additional radiation therapy,

          4. Patients who refuse other accepted available treatments such as surgery or narcotics
             for pain alleviation.

          5. Patient with NRS (0-10 scale) pain score â‰¥ 4 irrespective of medication

          6. Targeted tumor(s) are ExAblate device accessible and are located in ribs, extremities
             (excluding joints), pelvis, shoulders and in the posterior aspects of the following
             spinal vertebra: Lumbar vertebra (L3 - L5), Sacral vertebra (S1 - S5)

          7. Targeted tumor (treated) size up to 55 cm2 in surface area

          8. Patient whose targeted (treated) lesion is on bone and the interface between the bone
             and lesion is deeper than 10-mm from the skin.

          9. Targeted (treated) tumor clearly visible by non-contrast MRI, and ExAblate MRgFUS
             device accessible

         10. Able to communicate sensations during the ExAblate treatment

         11. Patients on ongoing chemotherapy regimen for at least 1 month at the time of
             eligibility:

             - with same chemotherapy regimen (as documented from patient medical dossier),

             And

             - Worst pain NRS still &gt;= 4

             And

             - do NOT plan to initiate a new chemotherapy for pain palliation should be eligible
             for the study.

         12. No radiation therapy to targeted (most painful) lesion in the past two weeks

         13. Bisphosphonate intake should remain stable throughout the study duration.

         14. Patients will have from 1 to 5 painful lesions and only the most painful lesion will
             be treated.

         15. Patients with persistent distinguishable pain associated with 1 site to be treated (if
             patient has pain from additional sites, the pain from the additional sites must be
             evaluated as being less intense by at least 2 points on the NRS compared to the site
             to be treated).

        Exclusion Criteria:

          1. Patients who either

               -  Need surgical stabilization of the affected bony structure (&gt;7 fracture risk
                  score, see Section 7.3) OR

               -  Targeted tumor is at an impending fracture site (&gt;7 on fracture risk score, see
                  Section 7.3).

             OR

             - Patients with surgical stabilization of tumor site with metallic hardware

          2. More than 5 painful lesions, or more than 1 requiring immediate localized treatment

          3. Targeted (treated) tumor is in the skull

          4. Patients on dialysis

          5. Patients with life expectancy &lt; 3-Months

          6. patients with an acute medical condition (e.g., pneumonia, sepsis) that is expected to
             hinder them from completing this study.

          7. Patients with unstable cardiac status including:

               -  Unstable angina pectoris on medication

               -  Patients with documented myocardial infarction within six months of protocol
                  entry

               -  Congestive heart failure requiring medication (other than diuretic)

               -  Patients on anti-arrhythmic drugs

          8. Severe hypertension (diastolic BP &gt; 100 on medication)

          9. Patients with standard contraindications for MR imaging such as non-MRI compatible
             implanted metallic devices including cardiac pacemakers, size limitations (weight &gt;250
             pounds), etc.

         10. Patients with an active infection or severe hematological, neurological, or other
             uncontrolled disease.

         11. Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium or
             Magnevist) including advanced kidney disease

         12. KPS Score &lt; 60 (See &quot;Definitions&quot; below)

         13. Severe cerebrovascular disease (multiple CVA or CVA within 6 months)

         14. Individuals who are not able or willing to tolerate the required prolonged stationary
             position during treatment (approximately 2 hrs.)

         15. Target (treated) tumor is less then 1cm from nerve bundles, bowels or bladder.

         16. Are participating or have participated in another clinical trial in the last 30 days

         17. Patients initiating a new chemotherapy regime, or radiation (for the targeted most
             painful lesion) within the last 2 weeks

         18. Patients unable to communicate with the investigator and staff.

         19. Patients with persistent undistinguishable pain (pain source unidentifiable)

         20. Targeted (treated) tumor surface area &gt;= 55 cm2

         21. Patient whose bone-lesion interface is &lt; 10-mm from the skin

         22. Targeted (treated) tumor NOT visible by non-contrast MRI,

         23. Targeted (most painful) tumor Not accessible to ExAblate

         24. The targeted tumor is less than 2 points more painful compared to other painful
             lesions on the site specific NRS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0987</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University MRI &amp; Diagnostic Imaging Centers</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam medical Center -The Pain palliation unit</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rome &quot;La Sapienza&quot;</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov State Research Institute of Oncology</name>
      <address>
        <city>Rostov on Don</city>
        <zip>344037</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N. N. Petrov Institute of Oncology</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Korea, Republic of</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 2, 2008</study_first_submitted>
  <study_first_submitted_qc>April 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2008</study_first_posted>
  <results_first_submitted>August 13, 2018</results_first_submitted>
  <results_first_submitted_qc>October 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 14, 2018</results_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone Cancer</keyword>
  <keyword>Pain Palliation</keyword>
  <keyword>Metastasis</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>cancer related Pain</keyword>
  <keyword>Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 147 subjects enrolled (signed consent), 23 subjects failed additional study requirements and 9 subjects exited after randomization but prior to treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ExAblate Treatment Arm</title>
          <description>ExAblate 2000: MR guided focused ultrasound</description>
        </group>
        <group group_id="P2">
          <title>ExAblate Sham Control Arm</title>
          <description>ExAblate 2000: MR guided focused ultrasound sham</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ExAblate Treatment Arm</title>
          <description>ExAblate 2000: MR guided focused ultrasound</description>
        </group>
        <group group_id="B2">
          <title>ExAblate Sham Control Arm</title>
          <description>ExAblate 2000: MR guided focused ultrasound sham</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="87"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="115"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.7" spread="13.3"/>
                    <measurement group_id="B2" value="56.8" spread="10.5"/>
                    <measurement group_id="B3" value="57.8" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Responders</title>
        <description>Using the Numerical Rating Score (NRS) for pain (0 being no pain and 10 being worst imaginable pain), each subject was rated as a Responder or Non-responder. A responder is defined as a subject with a reduction in NRS worst score from baseline of two (2) or more points, and no increase in pain medication use.</description>
        <time_frame>3 months post treatment</time_frame>
        <population>115 subjects were underwent treatment. Of these, 4 subjects terminated treatment prior to full completion. These 4 subjects are excluded from the efficacy analysis. An additional 4 subjects were found to have been enrolled in the study more than once. In a pre-PMA meeting with FDA, it was agreed upon to exclude these 4 subjects from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ExAblate Treatment Arm</title>
            <description>ExAblate 2000: MR guided focused ultrasound</description>
          </group>
          <group group_id="O2">
            <title>ExAblate Sham Control Arm</title>
            <description>ExAblate 2000: MR guided focused ultrasound sham</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Responders</title>
          <description>Using the Numerical Rating Score (NRS) for pain (0 being no pain and 10 being worst imaginable pain), each subject was rated as a Responder or Non-responder. A responder is defined as a subject with a reduction in NRS worst score from baseline of two (2) or more points, and no increase in pain medication use.</description>
          <population>115 subjects were underwent treatment. Of these, 4 subjects terminated treatment prior to full completion. These 4 subjects are excluded from the efficacy analysis. An additional 4 subjects were found to have been enrolled in the study more than once. In a pre-PMA meeting with FDA, it was agreed upon to exclude these 4 subjects from the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Change in Medication Use</title>
        <description>Medication Use change reported from baseline until of study. Medication use is quantified by &quot;morphine equivalent usage&quot; (measured separately from Responder/Non-responder definition for the primary endpoint)</description>
        <time_frame>3 months post treatment</time_frame>
        <population>Only 26 of the 81 subjects in ExAblate treatment arm and 6 of 26 in the sham arm were taking non-opioid medication at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>ExAblate Treatment Arm</title>
            <description>ExAblate 2000: MR guided focused ultrasound</description>
          </group>
          <group group_id="O2">
            <title>ExAblate Sham Control Arm</title>
            <description>ExAblate 2000: MR guided focused ultrasound sham</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Change in Medication Use</title>
          <description>Medication Use change reported from baseline until of study. Medication use is quantified by &quot;morphine equivalent usage&quot; (measured separately from Responder/Non-responder definition for the primary endpoint)</description>
          <population>Only 26 of the 81 subjects in ExAblate treatment arm and 6 of 26 in the sham arm were taking non-opioid medication at baseline.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (QOL) as Measured by Change in Bodily Pain Inventory (BPI) From Baseline</title>
        <description>The BPI-QOL questionnaire is designed to show the severity and interference of pain in the lives of patients. This is a 7-item questionnaire that asks respondents the extent to which pain interferes with their general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life using a 0-10 numerical rating scale in which 0 represents 'does not interfere' and 10 indicates 'completely interferes'. Responses to the 7 items are averaged to form the pain interference scale score. Lower scores are better, showing less interference in daily activities while higher scores show more interference and hence worse outcomes.</description>
        <time_frame>3 months post treatment</time_frame>
        <population>115 subjects were underwent treatment. Of these, 4 subjects terminated treatment prior to full completion. These 4 subjects are excluded from the efficacy analysis. An additional 4 subjects were found to have been enrolled in the study more than once. In a pre-PMA meeting with FDA, it was agreed upon to exclude these 4 subjects from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ExAblate Treatment Arm</title>
            <description>ExAblate 2000: MR guided focused ultrasound</description>
          </group>
          <group group_id="O2">
            <title>ExAblate Sham Control Arm</title>
            <description>ExAblate 2000: MR guided focused ultrasound sham</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (QOL) as Measured by Change in Bodily Pain Inventory (BPI) From Baseline</title>
          <description>The BPI-QOL questionnaire is designed to show the severity and interference of pain in the lives of patients. This is a 7-item questionnaire that asks respondents the extent to which pain interferes with their general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life using a 0-10 numerical rating scale in which 0 represents 'does not interfere' and 10 indicates 'completely interferes'. Responses to the 7 items are averaged to form the pain interference scale score. Lower scores are better, showing less interference in daily activities while higher scores show more interference and hence worse outcomes.</description>
          <population>115 subjects were underwent treatment. Of these, 4 subjects terminated treatment prior to full completion. These 4 subjects are excluded from the efficacy analysis. An additional 4 subjects were found to have been enrolled in the study more than once. In a pre-PMA meeting with FDA, it was agreed upon to exclude these 4 subjects from the analysis.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.8"/>
                    <measurement group_id="O2" value=".3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ExAblate Treatment Arm</title>
          <description>ExAblate 2000: MR guided focused ultrasound</description>
        </group>
        <group group_id="E2">
          <title>ExAblate Sham Control Arm</title>
          <description>ExAblate 2000: MR guided focused ultrasound sham</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>8 subjects died due to cancer progression, unrelated to study procedures.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Transient congnitive decline observed pre treatment resulting in gamma knife resection of brain metastasis.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Surgery for fracture at ExAblate-treatment site</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin burn</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pain/discomfort</sub_title>
                <counts group_id="E1" events="48" subjects_affected="46" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Numbness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Neuropathy/leg pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nadir Alikacem</name_or_title>
      <organization>InSightec</organization>
      <phone>214-630-2000</phone>
      <email>nadira@insightec.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

